Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke M, Pavel ME, Singh S (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Book Volume: 106
Pages Range: 151-151
Authors with CRIS profile
Involved external institutions
Novartis AG
Switzerland (CH)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
Dana–Farber Cancer Institute
United States (USA) (US)
Sunnybrook Health Sciences Centre
Canada (CA)
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
Royal North Shore Hospital (RNSH)
Australia (AU)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
Novartis Pharma S.A.S.
France (FR)
Istituto Clinico Humanitas
Italy (IT)
Switzerland (CH)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
Dana–Farber Cancer Institute
United States (USA) (US)
Sunnybrook Health Sciences Centre
Canada (CA)
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
Royal North Shore Hospital (RNSH)
Australia (AU)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
Novartis Pharma S.A.S.
France (FR)
Istituto Clinico Humanitas
Italy (IT)
How to cite
APA:
Chan, D.L., Yao, J.C., Carnaghi, C., Buzzoni, R., Herbst, F., Ridolfi, A.,... Singh, S. (2018). Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 151-151).
MLA:
Chan, D. L., et al. "Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials." 2018. 151-151.
BibTeX: Download